Concurrent intravenous immunoglobulin and platelet transfusion for refractory alloimmune thrombocytopenia in patients undergoing allogeneic hematopoietic stem cell transplantation
Continuous intravenous immunoglobulin and platelet infusions over 48 h may be able to overcome life-threatening refractory alloimmune thrombocytopenia in transplant patients and may provide a bridging measure until platelet engraftment or for life-threatening hemorrhage or invasive procedures with high bleeding risk.
Authors
- Rajat Bansal (ORCID: https://orcid.org/0000-0001-9042-0006)
- Muhammad Kashif Amin (ORCID: https://orcid.org/0000-0002-4052-7339)
- Al-Ola A. Abdallah (ORCID: https://orcid.org/0000-0002-6603-185X)
- Leyla Shune (ORCID: https://orcid.org/0000-0003-1650-1873)
- Haitham Abdelhakim
- Muhammad Umair Mushtaq (ORCID: https://orcid.org/0000-0001-8122-0563)
- Joseph P. McGuirk (ORCID: https://orcid.org/0000-0002-0539-4796)
- Joe S Al-Ramahi
- Maggie Nelson
- Sunil Abhyankar (ORCID: https://orcid.org/0000-0002-8578-1226)
- Nausheen Ahmed (ORCID: https://orcid.org/0000-0003-4336-4982)
- Moazzam Shahzad (ORCID: https://orcid.org/0000-0002-9609-6160)
- Anurag K. Singh (ORCID: https://orcid.org/0000-0002-6703-5115)
- Abhinav Vyas
Institutions
- University of Kansas Medical Center (US)
- Cellular Therapeutics (United Kingdom) (GB)
Publication Details
- Journal
- Hematology Transfusion and Cell Therapy
- Published
- 2025-08-09
- DOI
- https://doi.org/10.1016/j.htct.2025.103961
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00